This study will generate comparative data for 0.5-mg ranibizumab using pro re nata dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 and will provide efficacy and safety data for 0.5-mg ranibizumab using pro re nata dosing, administered with or without adjunctive laser treatment, over 24 months in patients with visual impairment due to macular edema (ME) secondary to BRVO.

Spectral domain high-definition optical coherence tomography (OCT) images will be explored to gain insights into predictive factors for disease progression and the possibility of reduced monitoring will be assessed in Year 2. The results of this open-label study will provide long-term safety and efficacy data to further guide recommendations on the use of ranibizumab for this indication. The primary objective is to evaluate the efficacy of an individualized stabilization criteria-driven pro re nata dosing regimen with 0.5 mg ranibizumab as assessed by the mean best-corrected visual acuity (BCVA) change at Month 12 compared to Baseline.

Privacy policy

Pursuant to the Personal Data Protection Act 15/1999 of 13 December, we inform you that the personal data requested will be contained in a file owned by the Barcelona Macula Foundation, registered with the Data Protection Agency. The right to access, rectify, cancel or oppose recognized by the Personal Data Protection Act 15/1999 of 13 December and in the regulations implementing this Act must be exercised in writing, providing a copy of your identity card, to the Barcelona Macula Foundation: Research for Vision, by post (to C/ Horaci, 41-43, Esc B, 08022, Barcelona, Spain) indicating "Data Protection" on the envelope, or by email to info@barcelonamaculafound.org.

Search

This website uses own and third party cookies to give you the best experience when you visit our website. By continuing to use this website, you consent to our use of these cookies.Accept